Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Unternehmen & Branche
| Name | TScan Therapeutics, Inc. |
|---|---|
| Ticker | TCRX |
| CIK | 0001783328 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 64,5 Mio. USD |
| Beta | 1,02 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 10,325,000 | -129,766,000 | -1.00 | 228,789,000 | 123,123,000 |
| 2025-09-30 | 10-Q | 2,511,000 | -35,710,000 | -0.28 | 262,225,000 | 144,021,000 |
| 2025-06-30 | 10-Q | 3,076,000 | -36,952,000 | -0.28 | 298,561,000 | 176,714,000 |
| 2025-03-31 | 10-Q | 2,171,000 | -34,127,000 | -0.26 | 332,709,000 | 210,202,000 |
| 2024-12-31 | 10-K | 2,816,000 | -127,499,000 | -1.14 | 371,118,000 | 240,970,000 |
| 2024-09-30 | 10-Q | 1,049,000 | -29,887,000 | -0.25 | 348,027,000 | 229,087,000 |
| 2024-06-30 | 10-Q | 536,000 | -31,661,000 | -0.28 | 374,871,000 | 255,221,000 |
| 2024-03-31 | 10-Q | 566,000 | -30,142,000 | -0.32 | 240,832,000 | 122,967,000 |
| 2023-12-31 | 10-K | 21,049,000 | -89,218,000 | -1.36 | 272,149,000 | 150,867,000 |
| 2023-09-30 | 10-Q | 3,887,000 | -22,997,000 | -0.24 | 291,379,000 | 168,961,000 |
| 2023-06-30 | 10-Q | 3,148,000 | -24,045,000 | -0.51 | 316,923,000 | 190,607,000 |
| 2023-03-31 | 10-Q | 6,803,000 | -22,563,000 | -0.93 | 173,577,000 | 78,018,000 |
| 2022-12-31 | 10-K | 13,535,000 | -66,221,000 | -2.75 | 199,091,000 | 99,434,000 |
| 2022-09-30 | 10-Q | 3,363,000 | -16,245,000 | -0.67 | 165,454,000 | 116,658,000 |
| 2022-06-30 | 10-Q | 4,056,000 | -15,097,000 | -0.63 | 152,415,000 | 131,652,000 |
| 2022-03-31 | 10-Q | 3,021,000 | -16,156,000 | -0.67 | 168,204,000 | 145,694,000 |
| 2021-12-31 | 10-K | 10,141,000 | -48,625,000 | -4.17 | 188,107,000 | 160,778,000 |
| 2021-09-30 | 10-Q | 2,412,000 | -15,839,000 | -0.80 | 204,889,000 | 174,074,000 |
| 2021-06-30 | 10-Q | 2,848,000 | -10,674,000 | -7.69 | 130,007,000 | -60,030,000 |
| 2021-03-31 | 10-Q | 2,027,000 | -7,912,000 | -49,922,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 6,232 | 0.90 | 5,601.94 | +0,9% | |
| 2025-12-22 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 75,500 | 0.90 | 67,950.00 | +10,4% | |
| 2025-12-19 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 80,069 | 0.90 | 71,974.02 | +11,1% | |
| 2025-05-20 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 1,200,000 | 1.20 | 1,440,000.00 | +221,4% | |
| 2025-05-19 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 1,388,794 | 1.20 | 1,666,552.80 | +256,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.